These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37945744)

  • 1. Functional analysis of a putative HER2-associated expressed enhancer, Her2-Enhancer1, in breast cancer cells.
    Rojhannezhad M; Soltani BM; Vasei M; Ghorbanmehr N; Mowla SJ
    Sci Rep; 2023 Nov; 13(1):19516. PubMed ID: 37945744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
    PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The "HER2-PI3K/Akt-FASN Axis" regulated malignant phenotype of colorectal cancer cells.
    Li N; Bu X; Wu P; Wu P; Huang P
    Lipids; 2012 Apr; 47(4):403-11. PubMed ID: 22218925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
    Hosonaga M; Arima Y; Sugihara E; Kohno N; Saya H
    Cancer Sci; 2014 Jul; 105(7):779-87. PubMed ID: 24754246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
    Zhang W; Ding W; Chen Y; Feng M; Ouyang Y; Yu Y; He Z
    Acta Biochim Biophys Sin (Shanghai); 2011 Aug; 43(8):647-53. PubMed ID: 21712253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fisetin induces apoptosis in breast cancer MDA-MB-453 cells through degradation of HER2/neu and via the PI3K/Akt pathway.
    Guo G; Zhang W; Dang M; Yan M; Chen Z
    J Biochem Mol Toxicol; 2019 Apr; 33(4):e22268. PubMed ID: 30431692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
    Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
    Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7].
    Zheng L; Ren JQ; Chen Q; Zhang HP; Zhu HG
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):594-7. PubMed ID: 15634518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphoinositide 3-kinase targeting by the beta galactoside binding protein cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.
    Wells V; Mallucci L
    Breast Cancer Res; 2009; 11(1):R2. PubMed ID: 19133120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-18a-5p attenuates HER2-positive breast cancer development by regulating PI3K/AKT pathway.
    Liu Y; Yang H
    Cancer Biol Ther; 2023 Dec; 24(1):2224512. PubMed ID: 37394766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
    Li H; Wang J; Yi Z; Li C; Wang H; Zhang J; Wang T; Nan P; Lin F; Xu D; Qian H; Ma F
    Eur J Cancer; 2021 Mar; 145():92-108. PubMed ID: 33429148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AKT-mediated phosphorylation of Sox9 induces Sox10 transcription in a murine model of HER2-positive breast cancer.
    Al-Zahrani KN; Abou-Hamad J; Pascoal J; Labrèche C; Garland B; Sabourin LA
    Breast Cancer Res; 2021 May; 23(1):55. PubMed ID: 33985544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
    Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
    Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.
    Millis SZ; Ikeda S; Reddy S; Gatalica Z; Kurzrock R
    JAMA Oncol; 2016 Dec; 2(12):1565-1573. PubMed ID: 27388585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
    Way TD; Kao MC; Lin JK
    J Biol Chem; 2004 Feb; 279(6):4479-89. PubMed ID: 14602723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.
    Young CD; Arteaga CL; Cook RS
    Breast Cancer Res; 2015 Dec; 17():148. PubMed ID: 26637440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.
    Ruiz-Saenz A; Dreyer C; Campbell MR; Steri V; Gulizia N; Moasser MM
    Cancer Res; 2018 Jul; 78(13):3645-3658. PubMed ID: 29760043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling.
    Le XF; Lammayot A; Gold D; Lu Y; Mao W; Chang T; Patel A; Mills GB; Bast RC
    J Biol Chem; 2005 Jan; 280(3):2092-104. PubMed ID: 15504738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.